JPRN-jRCT2031210162进行中（未招募）2 期
A phase II, open-Label, extension study of NS-089/NCNP-02 in patients with Duchenne muscular dystrophy
Taira Masafumi0 个研究点目标入组 6 人开始时间: 2021年6月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- •1. Patient completed Study NCNP/DMT02
排除标准
- •1. Patient had any serious adverse events in Study NCNP/DMT02 that, in the opinion of the Investigator and/or Sponsor, was probably or definitely related to NS-089/NCNP-02 use and precludes safe use of NS-089/NCNP-02 for the patient in this study.
- •2. Patient had a treatment which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NCNP/DMT02.
- •3. Patient took any other investigational drugs after completion of Study NCNP/DMT02.
- •4. Patient was judged by the investigator and/or the Sponsor that it was not appropriate to participate in the extension study for other reasons.
研究者
相似试验
进行中（未招募）
2 期
Extension Study of NS-089/NCNP-02 in DMDDuchenne Muscular Dystrophy (DMD)NCT05135663Nippon Shinyaku Co., Ltd.6
已完成
2 期
A Phase II/III Open-label Extension Study of NPC-09 (N-acetylneuraminic acid) in Patients with GNE Myopathy (GNEM)GNE myopathy (Distal myopathy with rimmed vacuoles (DMRV), hereditary inclusion body myopathy (hIBM) or Nonaka disease)JPRN-UMIN000026354Tohoku University Hospital, Department of Neurology19
进行中（未招募）
1 期
A Long-Term Study with GLM101 in Patients with PMM2-CDGPMM2-CDGMedDRA version: 20.0Level: LLTClassification code: 10027426Term: Metabolic disorder NOS Class: 10027433CTIS2024-512171-12-00Glycomine Inc.33
招募中
2 期
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia2024-511331-96-00Arrowhead Pharmaceuticals Inc.178
进行中（未招募）
1 期
A Long-Term Study to Evaluate ARO-APOC3 in Adults with DyslipidemiaEUCTR2022-001135-85-HUArrowhead Pharmaceuticals, Inc.582